Phase 3 trial reveals semaglutide, an obesity drug, significantly reduces knee osteoarthritis pain in obese adults.

A phase 3 trial published in The New England Journal of Medicine found that semaglutide, a drug for obesity, significantly alleviates knee osteoarthritis pain in obese adults. Over 68 weeks, participants lost an average of 13.7% of their body weight and reported a notable reduction in pain. Although results indicate semaglutide may improve physical function and delay surgery, it is not currently approved for osteoarthritis treatment in the U.S. Further research is needed.

October 30, 2024
28 Articles